Betamethasone

• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 Phase III 10 countries Pfizer Inc.
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting
  2024-514648-10-00 Phase III 6 countries Pfizer Inc.
• A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting
  2022-500570-33-00 Phase III 1 country Region Västerbotten; Umea University
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 Phase III 8 countries InflaRx GmbH
• Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis - RECORDS Ended
  2024-516407-16-00 Phase III 1 country Assistance Publique Hopitaux De Paris

Showing 1–7 of 7 trials